Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBAY CymaBay Therapeutics	$32.48	$32.44	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
CRVS Corvus Pharmaceuticals	$3.94 -1.1%	$3.84	$1.75 ▼ $10.00	$269.27M	0.58	827,273 shs	313,955 shs
EPIX ESSA Pharma	$1.74 +2.1%	$1.71	$1.40 ▼ $7.88	$77.24M	1.56	339,578 shs	48,109 shs
IFRX InflaRx	$0.81 -0.7%	$1.20	$0.71 ▼ $2.82	$53.87M	1.29	289,375 shs	56,884 shs
XERS Xeris Biopharma	$4.76 +0.5%	$4.69	$2.05 ▼ $6.07	$742.83M	0.66	2.04 million shs	1.08 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
CRVS Corvus Pharmaceuticals	0.00%	+1.16%	+4.93%	+38.07%	+121.07%
EPIX ESSA Pharma	0.00%	+0.29%	+1.46%	+17.23%	-64.08%
IFRX InflaRx	0.00%	-0.35%	-5.29%	-20.30%	-50.61%
XERS Xeris Biopharma	0.00%	+1.17%	+7.34%	+7.82%	+128.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	2.4894 of 5 stars	3.5	1.0	0.0	0.0	1.6	3.3	0.6
EPIX ESSA Pharma	1.3226 of 5 stars	2.0	2.0	0.0	0.0	0.6	2.5	1.3
IFRX InflaRx	2.7029 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	0.6
XERS Xeris Biopharma	3.9058 of 5 stars	3.4	1.0	0.0	4.2	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBAY CymaBay Therapeutics	0.00	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	281.19% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	15.27% Upside
IFRX InflaRx	3.00	Buy	$6.60	719.88% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	31.44% Upside

Current Analyst Ratings Breakdown

Latest XERS, CRVS, EPIX, IFRX, and CBAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
5/8/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
4/29/2025	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
IFRX InflaRx	$180K	300.22	N/A	N/A	$1.13 per share	0.71
XERS Xeris Biopharma	$203.07M	3.66	N/A	N/A	($0.20) per share	-23.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	N/A
CRVS Corvus Pharmaceuticals	-$62.29M	-$0.98	N/A	N/A	N/A	N/A	-24.04%	-13.90%	8/5/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-23.48%	-22.86%	8/4/2025 (Estimated)
IFRX InflaRx	-$49.85M	-$0.82	N/A	N/A	N/A	N/A	-64.17%	-53.39%	8/6/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)

Latest XERS, CRVS, EPIX, IFRX, and CBAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBAY CymaBay Therapeutics	N/A	10.96	10.96
CRVS Corvus Pharmaceuticals	N/A	4.90	4.90
EPIX ESSA Pharma	N/A	67.15	67.15
IFRX InflaRx	N/A	5.28	4.86
XERS Xeris Biopharma	N/A	1.72	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBAY CymaBay Therapeutics	95.03%
CRVS Corvus Pharmaceuticals	46.64%
EPIX ESSA Pharma	75.12%
IFRX InflaRx	42.39%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
CBAY CymaBay Therapeutics	7.00%
CRVS Corvus Pharmaceuticals	28.50%
EPIX ESSA Pharma	15.50%
IFRX InflaRx	16.30%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	48.74 million	Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
XERS Xeris Biopharma	290	156.38 million	146.27 million	Optionable

XERS, CRVS, EPIX, IFRX, and CBAY Headlines

Recent News About These Companies

Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $6.25

July 1, 2025 | americanbankingnews.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from Analysts

June 28, 2025 | marketbeat.com

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

June 18, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying Activity

June 17, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

June 17, 2025 | insidertrades.com

Kevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

June 16, 2025 | marketbeat.com

Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings

June 9, 2025 | marketbeat.com

Leerink Partnrs Cuts Earnings Estimates for Xeris Biopharma

June 6, 2025 | marketbeat.com

Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug

June 4, 2025 | chicagobusiness.comC

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 3, 2025 | finance.yahoo.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

4XERS : Earnings Outlook For Xeris Biopharma Holdings

May 7, 2025 | benzinga.com

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025 | seekingalpha.com

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit

April 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, CRVS, EPIX, IFRX, and CBAY Company Descriptions

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$3.94 -0.05 (-1.13%)

Closing price 07/3/2025 02:54 PM Eastern

Extended Trading

$3.96 +0.02 (+0.51%)

As of 07/3/2025 04:51 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

ESSA Pharma NASDAQ:EPIX

$1.74 +0.04 (+2.06%)

As of 07/3/2025 01:01 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

InflaRx NASDAQ:IFRX

$0.80 -0.01 (-0.74%)

Closing price 07/3/2025 03:37 PM Eastern

Extended Trading

$0.80 0.00 (0.00%)

As of 07/3/2025 04:39 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Xeris Biopharma NASDAQ:XERS

$4.76 +0.03 (+0.53%)

Closing price 07/3/2025 02:59 PM Eastern

Extended Trading

$4.76 0.00 (0.00%)

As of 07/3/2025 04:50 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time